Gene-environment Interactions Modulating Cortical And Cognitive Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$618,300.00
Summary
A feature of many major brain disorders, including schizophrenia and dementia, is disruption of cognition. A key brain area impacted in such cognitive disorders is the prefrontal cortex. This project will use clinically translatable touchscreen to understand how this aspect of brain dysfunction causes abnormal cognition. We will investigate the mechanisms involved, using highly innovative approaches, which will contribute to the development of new treatments for such cognitive disorders.
Controlling Intrusive Images In Psychopathologies: Disarming Symptoms And Enhancing Treatment
Funder
National Health and Medical Research Council
Funding Amount
$285,085.00
Summary
This proposal will conduct the first pre-clinical study disarming symptoms and enhancing treatment of many psychopathologies by controlling the strength of mental imagery. This study represents the first attempt to alleviate symptoms by developing a cognitive-neuroscience vaccine to control the strength of traumatic imagery and to show a causative means of enhancing imagery strength to boost the success rate of cognitive therapy involving imagery.
Defining The Epigenetic Origins Of Maternally Inherited Disease.
Funder
National Health and Medical Research Council
Funding Amount
$731,162.00
Summary
Epigenetic (non genetic) changes to the DNA in sperm and eggs can alter outcomes in children. Despite the potential for drugs and diet to mediate some of these inherited effects, the processes involved are very poorly understood. By determining the mechanisms that regulate epigenetic inheritance, this project will improve our understanding of how epigenetic mechanisms acting in the parent, can mediate inherited disease and life-long health outcomes in our children.
Discovering Deep Sleep Genes And Determining Their Roles For Preserving Cognitive Functions
Funder
National Health and Medical Research Council
Funding Amount
$484,901.00
Summary
Our mental well-being is largely tied to our sleep quality, and most cognitive disorders are also associated with poor sleep processes. Yet, we still do not know how sleep quality safeguards cognitive function. We will uncover genes that play a restorative role during deep sleep, and determine how genetic control of these deep sleep genes modulates selective attention in an animal model. Our results will suggest novel therapies for treating sleep disorders and associated diseases of the brain.
Enhancing The Treatment Of Anxiety: The Role Of Mental Imagery
Funder
National Health and Medical Research Council
Funding Amount
$246,491.00
Summary
This proposal will conduct the first pre-clinical study augmenting the effectiveness of cognitive behaviour therapy (CBT) in the treatment of anxiety disorders using mental imagery. There is an urgent need to develop means to increase the success rate of CBT. This study will utilise recent developments in cognitive neuroscience to show that mental imagery plays an important role in the mechanisms of CBT.
One-session Treatment For Specific Phobias In Pre-school Children: Improving Access And Long-term Mental Health Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$567,745.00
Summary
This project aims to conduct the first randomised controlled trial of a modified-one session treatment (OST) for preschoolers with specific phobias (SP). SPs are highly prevalent (~10%), onset very early in life (~3 years) and predict a host of mental illness later in life. OST for SPs is well-established for older children (>7 years), yet is currently untested with pre-school aged children.
A Randomized Controlled Trial Of Three Treatments For Anorexia Nervosa In Adults
Funder
National Health and Medical Research Council
Funding Amount
$606,447.00
Summary
This study will be the first to evaluate three promising new treatments for anorexia nervosa (AN) and anorexic type eating disorders in adults. The first treatment is a new therapy called Enhanced Cognitive Behaviour Therapy. The second treatment, the Maudsley Cognitive Motivational Therapy, was designed specifically to treat AN and the third treatment is called non-specific supportive clinical management. The study will be in the form of a multi-centre randomised treatment trial.
Increasing The Efficacy Of Treatment For Socially Anxious Youth Through Theoretically Derived Improvements
Funder
National Health and Medical Research Council
Funding Amount
$971,747.00
Summary
Social anxiety has a severe impact on young people. Although we have good treatments for most anxious youth, those with social anxiety show the least change. The proposed project will evaluate the benefits of a new treatment for socially anxious young people based on current understanding of the causes of this disorder. The new treatment will have better effects than traditional therapy and will lead to increased knowledge of the causes of this disorder.
Rumination And Deficits In The Recall Of Positive Autobiographical Memories In Depression
Funder
National Health and Medical Research Council
Funding Amount
$263,295.00
Summary
The prevalence of depression is increasing and risk of recurrence exceeds 80%. The social and economic burden of depression highlight the urgent need to advance understanding of the habits of thought and memory that keep people feeling depressed, so that psychologists can treat depression more effectively. This project will explain why depressed people feel worse when they recall happy memories. The outcomes will extend theory and guide the improvement of treatments for this condition.
Investigating The Impact Of Coincident Modulation Of Adenosine And Glutamate Receptors On Neuronal Activity – Implications For CNS Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$648,447.00
Summary
Dementia in particular Alzheimer's disease, is one of the leading causes of death. There remains a need for new drugs to treat both symptoms and disease progression. Two receptors in the brain, the adenosine A1 (A1AR) and metabotropic glutamate 5 (mGlu5) are suggested to be promising new drug targets for dementia. In order to better develop drugs that target these receptors, we will develop a better understanding of activity of these receptors under conditions of health and disease.